Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 – 10 February 2022 | European Medicines Agency – European Medicines…
PRAC recommends suspending hydroxyethyl-starch solutions for infusion from the market
EMAs safety committee (PRAC) has recommended that marketing authorisations for hydroxyethyl-starch (HES) solutions for infusion should be suspended across the European Union (EU). These products were authorised as an addition to other treatments for plasma volume replacements following acute (sudden) blood loss.
The safety of HES solutions for infusion was reviewed in two separate procedures in 2013, and a number of restrictions and measures to minimise the risk of kidney injury and death in certain patients (those critically ill, with burn injuries or with sepsis, i.e. a bacterial infection in the blood) were put in place at the time.
As a result of a third review conducted in 2018, the use of HES solutions for infusion was further restricted to accredited hospitals, and healthcare professionals prescribing or administering the medicines had to be trained in their appropriate use. Companies marketing HES solutions for infusion were also requested to conduct a drug utilisation study to check that the restrictions were adhered to in clinical practice, and to submit the results of this study to EMA.
The PRAC has now reviewed the results from this study, which show that HES solutions for infusion are still being used outside the recommendations included in the product information. In view of the serious risks that certain patient populations are still exposed to, the PRAC has therefore recommended the suspension of the marketing authorisations for HES solutions for infusion in the EU.
More information is available inEMAspublic health communication.
The PRAC has started a review of the safety of Janus kinase (JAK) inhibitors used to treat several chronic inflammatory disorders (rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, ulcerative colitis and atopic dermatitis).
The review was prompted by the final results from a clinical trial (study A3921133) of the JAK inhibitor Xeljanz (tofacitinib). The results showed that patients taking Xeljanz for rheumatoid arthritis and who were at risk of heart disease were more likely to experience a major cardiovascular problem (such as heart attack, stroke or death due to cardiovascular disease) and had a higher risk of developing cancer than those treated with medicines belonging to the class of TNF-alpha inhibitors. The study also showed that compared with TNF-alpha inhibitors, Xeljanz was associated with a higher risk of death due to any cause, serious infections and blood clots in the lungs and in deep veins (venous thromboembolism VTE).
In addition, preliminary findings from an observational study involving another JAK inhibitor, Olumiant (baricitinib), also suggest an increased risk of major cardiovascular problems and VTE in patients with rheumatoid arthritis treated with Olumiant compared with those treated with TNF-alpha inhibitors.
In the treatment of inflammatory disorders, Olumiant and other JAK inhibitors work in a similar way to Xeljanz. PRAC will therefore carry out a review to determine whether these risks are associated with all JAK inhibitors authorised in the EU for the treatment of inflammatory disorders1 and whether the marketing authorisations for these medicines should be amended.
Some measures to minimise these risks are already in place for Xeljanz as a result of a review finalised in 2020, which analysed the interim results of study A3921133. In addition, the product information for Xeljanz was further updated in 2021 to reflect the increased risk of major cardiovascular problems and cancer observed after the release of additional data from this study.
More information is available inEMAspublic health communication.
The PRAC is assessing reported cases of heavy menstrual bleeding (heavy periods) and absence of menstruation (amenorrhea) with the COVID-19 vaccines Comirnaty and Spikevax.
The Committee had previously analysed reports of menstrual (period) disorders in the context of the safety summary reports for COVID-19 vaccines approved in the EU and concluded at the time that the evidence did not support a causal link between these vaccines and menstrual disorders.
In view of spontaneous reports of menstrual disorders with both vaccines and of findings from the literature, the PRAC decided to further assess occurrences of heavy periods or amenorrhea following vaccination.
Menstrual disorders are very common and can occur with a wide range of underlying medical conditions as well as from stress and tiredness. Cases of these disorders have also been reported following COVID-19 infection.
Heavy periods may be defined as bleeding characterised by a volume, which may interfere with the persons physical, social, emotional and material quality of life. Amenorrhea may be defined as the absence of menstrual bleeding for three or more months in a row.
After reviewing the available evidence, thePRACdecided to request an in-depth evaluation of all available data, including reports fromspontaneous reporting systems,clinical trialsand the published literature.
At this stage, it is not yet clear whether there is a causal link between the COVID-19 vaccines and the reports of heavy periods or amenorrhea. There is also no evidence to suggest that COVID-19 vaccines affect fertility.
EMA will communicate further when more information becomes available.
The PRAC has adopted updated guidance on core requirements for risk management plans (RMPs) of COVID-19 vaccines.
As for any medicinal product that is authorised in the EU, companies need to submit their RMP when applying for a marketing authorisation to detail their plan for the post-marketing surveillance and what measures they must put in place to further characterise and manage risks. In the context of the pandemic, EMA adopted specific RMP guidance for COVID-19 vaccines, which complements theexisting guidelines on the RMP format in the EUand guidance ongood pharmacovigilance practices.
Following discussion at the PRAC, this guidance has been updated in light of the experience accrued during the pandemic to include specific considerations on:
The new version of the guidance is available on EMAs website.
As part of its advice on safety-related aspects to other EMA committees, thePRACdiscussed a direct healthcare professional communication (DHPC) containing important safety information for infliximab.
Advice to postpone use of live vaccines in infants exposed to infliximab during pregnancy or via breastfeeding
This DHPC informs healthcare professionals on the need to postpone the use of live vaccines in infants who are exposed to infliximab during pregnancy or via breastfeeding.
Infliximab is an anti-inflammatory medicine authorised for the treatment of adults with rheumatoid arthritis (an immune system disease causing inflammation of the joints), Crohns disease (a disease causing inflammation of the digestive tract), ulcerative colitis (a disease causing inflammation and ulcers in the lining of the gut), ankylosing spondylitis (a disease causing inflammation and pain in the joints of the spine), psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints) or psoriasis (a disease causing red, scaly patches on the skin). Infliximab is also authorised in patients aged between 6 and 17 years with severe, active Crohns disease or severely active ulcerative colitis, when they have not responded to or cannot take other medicines or treatments.
Following treatment during pregnancy, it has been reported that infliximab crosses the placenta and it has been detected in infants up to 12 months after birth. Live vaccines should not be given to infants for 12 months after birth if they have been exposed to infliximab during pregnancy. If infant infliximab serum levels are undetectable or infliximab administration was limited to the first trimester of pregnancy, administration of a live vaccine might be considered at an earlier time point if there is a clear clinical benefit for the individual infant.
Infliximab has also been detected at low levels in breast milk, therefore, administration of a live vaccine to a breastfed infant while the mother is receiving the medicine is not recommended unless infant infliximab serum levels are undetectable.
It is important that women treated with infliximab who become pregnant or who breastfeed their infant inform the healthcare professional responsible for vaccination of their infant about their treatment with infliximab.
The DHPC for infliximab will be forwarded to EMAs human medicines committee, theCHMP.
Following theCHMP decision, the DHPC will be disseminated to healthcare professionals by themarketing authorisation holders according to an agreed communication plan, and published on theDirect healthcare professional communicationspage and innational registersin the EU Member States.
1 Cibinqo (abrocitinib), Jyseleca (filgotinib), Olumiant (baricitinib), Rinvoq (upadacitinib) and Xeljanz (tofacitinib).
See the rest here:
Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 7 - 10 February 2022 | European Medicines Agency - European Medicines...
- European Union Special Representatives for the Sahel and the Horn of Africa visit Addis Ababa - EEAS - July 8th, 2025 [July 8th, 2025]
- Iceland : The 28th member state of the European Union ? Le Taurillon - treffpunkteuropa.de - July 8th, 2025 [July 8th, 2025]
- European Union's Caramel Market to Reach 606K Tons and $838M by 2035 - IndexBox - July 6th, 2025 [July 6th, 2025]
- European Union's Threaded Steel Articles Market to Grow at +1.4% CAGR, Reaching $4.4B by 2035 - IndexBox - July 6th, 2025 [July 6th, 2025]
- The European Union awards an additional 14.8 million in Aid to UNICEF to support the most vulnerable children and strengthen disaster preparedness in... - July 4th, 2025 [July 4th, 2025]
- Speech by President Antnio Costa at the opening ceremony of the Danish Presidency of the Council of the European Union - consilium.europa.eu - July 4th, 2025 [July 4th, 2025]
- Deepening structural reforms and reprioritising public spending can boost growth in the European Union - OECD - July 4th, 2025 [July 4th, 2025]
- Now Unfolding The Impact Of Russias Military Priorities On International Travel: Insights For US, China, European Union And CIS Markets: Here Is What... - July 4th, 2025 [July 4th, 2025]
- European Union's Butan-1-ol Market to Experience Slight Growth with +0.3% CAGR in Volume and +1.6% CAGR in Value from 2024 to 2035 - IndexBox - July 4th, 2025 [July 4th, 2025]
- China and the European Union Hold the 13th Round of High-level Strategic Dialogue - fmprc.gov.cn - July 4th, 2025 [July 4th, 2025]
- European Union's Cobalt Oxides and Hydroxides Market Expected to Grow steadily at +2.3% CAGR over the Next Decade - IndexBox - July 4th, 2025 [July 4th, 2025]
- European Union's Lubricating Oil Additives Market to Expand at a CAGR of +2.4% Through 2035, Reaching $103.1B in Market Value - IndexBox - July 2nd, 2025 [July 2nd, 2025]
- New spokesperson for the European Union Mission in Mozambique is from Minho - EEAS - July 2nd, 2025 [July 2nd, 2025]
- European Union nations call for stricter limits on sperm donation - Live Action | Pro-Life - June 29th, 2025 [June 29th, 2025]
- European Union's Cheese Market: Increasing Demand for Grated, Powdered, and Blue-Veined Cheeses to Drive Market Growth to 7M tons and $48.4B by 2035 -... - June 29th, 2025 [June 29th, 2025]
- European Union's Silver Market to See Slight Growth with +1.3% CAGR Driving Consumption Trends - IndexBox - June 29th, 2025 [June 29th, 2025]
- European Union's Grape Market to Witness Mild Growth with CAGR of +0.5% from 2024 to 2035 - IndexBox - June 29th, 2025 [June 29th, 2025]
- European Union Set to Redefine Budget Air Travel with Ambitious Policy Guaranteeing Free Carry-On Luggage and Greater Passenger Freedom on All EU and... - June 29th, 2025 [June 29th, 2025]
- European Union's Iron and Steel Slabs, Billets, and Blooms Market to Exhibit Slight Growth with CAGR of +0.4% through 2035 - IndexBox - June 29th, 2025 [June 29th, 2025]
- The United States has submitted a fresh trade deal proposal to the European Union - Forexlive | Forex News, Technical Analysis & Trading Tools - June 29th, 2025 [June 29th, 2025]
- Why Apple is revamping its App Store terms in the European Union - Fast Company - June 28th, 2025 [June 28th, 2025]
- Fiala: The European Union should not terminate the association agreement with Israel - European Newsroom - June 28th, 2025 [June 28th, 2025]
- European Union's Nitric and Sulphonitric Acids Market to Reach 1.5M Tons and $586M by 2035 - IndexBox - June 28th, 2025 [June 28th, 2025]
- European Union's Aniline Derivatives Market Expected to See +1.5% CAGR Growth Over Next Decade - IndexBox - June 28th, 2025 [June 28th, 2025]
- One-sided account of Israels actions in Gaza, Bnai Brith says of European Union report - JNS.org - June 28th, 2025 [June 28th, 2025]
- Importing Conflict into the European Union Not the Way to Peace, Hungarian PMs Political Director Says - The European Conservative - June 28th, 2025 [June 28th, 2025]
- After NATO Deal, How Far Will European Union Go For Trade Peace With Donald Trump - NDTV - June 28th, 2025 [June 28th, 2025]
- European Union divided over response to suspected Israeli rights breaches - Reuters - June 24th, 2025 [June 24th, 2025]
- The European Union and Canada open a new chapter in their cooperation - European Commission - June 24th, 2025 [June 24th, 2025]
- European Union military engagement in the Western Balkans: peacekeeping or strategic containment? EUs mission EUFOR Althea case study - PubAffairs... - June 24th, 2025 [June 24th, 2025]
- Lavrov announced the manifestation of rebellion in the controlled "herd" of NATO and of the European Union - EADaily - June 24th, 2025 [June 24th, 2025]
- Spain will ask the European Union to suspend the association agreement with Israel - Pressenza - International Press Agency - June 24th, 2025 [June 24th, 2025]
- European Union divided over response to suspected Israeli rights breaches - The Japan Times - June 24th, 2025 [June 24th, 2025]
- Israels appetite for war in Gaza threatens its relationship with the European Union - The Guardian - June 24th, 2025 [June 24th, 2025]
- Hybrid launch of 'The Routledge Guide to the European Union (2nd edition)' with Ian Bond, Mark Leonard and Armida van Rij - Centre for European Reform... - June 24th, 2025 [June 24th, 2025]
- The role of services of general interest (SGI) for competitiveness, social cohesion and democracy in the European Union - EESC - June 24th, 2025 [June 24th, 2025]
- European Union's Boring or Sinking Machinery Market to Reach 44K Units and $2.2B Value by 2035 - IndexBox - June 24th, 2025 [June 24th, 2025]
- European Union: AI Partnerships and DMA Enforcement Top of the Agenda for European Regulators - Wilson Sonsini - June 22nd, 2025 [June 22nd, 2025]
- European Union's Beverage Filtration Machinery Market to Reach 1.2M Units and $612M by 2035 - IndexBox - June 22nd, 2025 [June 22nd, 2025]
- European Union's Hydraulic Press Market Expected to Grow with 289K Units and $2.4B Value by 2035 - IndexBox - June 22nd, 2025 [June 22nd, 2025]
- Statement by the Ministers of Foreign Affairs of France, Germany, and the United Kingdom, together with the High Representative of the European Union... - June 22nd, 2025 [June 22nd, 2025]
- Rare earth access is the European Union's priority at China summit - Reuters - June 20th, 2025 [June 20th, 2025]
- Germany, Italy, Netherlands, Spain, Czech Republic, Denmark and Twenty One Countries in European Union Threatening to Suspend Israel Schengen Visa... - June 20th, 2025 [June 20th, 2025]
- European Union's Lifts and Elevators Market to Grow at a CAGR of +0.9% through 2035, Expected to Reach 665K Units - IndexBox - June 20th, 2025 [June 20th, 2025]
- European Union's Packaging Machinery Market to Increase at a CAGR of +2.2% Reaching $6.3B by 2035 - IndexBox - June 20th, 2025 [June 20th, 2025]
- The European Union announced the rejection of Russian gas at the wrong time: the price is approaching $ 500 - EADaily - June 20th, 2025 [June 20th, 2025]
- The European Union Watches from the Sidelines - inss.org.il - June 20th, 2025 [June 20th, 2025]
- How is disinformation addressed in the member states of the European Union? 27 country cases - EDMO.eu - June 18th, 2025 [June 18th, 2025]
- Literature review on actors of disinformation in the European Union - EDMO.eu - June 18th, 2025 [June 18th, 2025]
- Akriila and the European Union collaborate to give voice to Chiles clean energy future in new track The Power - EEAS - June 18th, 2025 [June 18th, 2025]
- Israel/Iran: Statement by the High Representative on behalf of the European Union - consilium.europa.eu - June 18th, 2025 [June 18th, 2025]
- Trump Drops Papers He Just Signed and Mistakenly Refers to the U.K. as The European Union - Mediaite - June 18th, 2025 [June 18th, 2025]
- In April, imports of plywood to European Union increase 5% - lesprom.com - June 18th, 2025 [June 18th, 2025]
- European Union warns of retaliation over Trumps steel tariff hike - The Indian Express - June 1st, 2025 [June 1st, 2025]
- News: NATO and the European Union unite for Ukraine at a NAC - PSC meeting, 28-May.-2025 - NATO - Homepage - June 1st, 2025 [June 1st, 2025]
- Its Time for Israel To Join the European Union - The Media Line - June 1st, 2025 [June 1st, 2025]
- Beijing-based Ambassadors of the European Political Community (EPC) met at the European Union Delegation to China - EEAS - June 1st, 2025 [June 1st, 2025]
- Tech tariffs? A brewing conflict with the European Union and within the Trump administration - Washington Examiner - June 1st, 2025 [June 1st, 2025]
- European Union on its way to reach a 54% GHG emissions reduction by 2030 - Enerdata - June 1st, 2025 [June 1st, 2025]
- Trump Advisor Jason Miller Warns of the Threat European Union Poses to Free Speech - floridianpress.com - June 1st, 2025 [June 1st, 2025]
- Trump says trade negotiations to begin soon between U.S. and European Union - MSNBC News - June 1st, 2025 [June 1st, 2025]
- European Union accuses TikTok of breaching digital rules with lack of transparency on ads - AP News - May 15th, 2025 [May 15th, 2025]
- What should the European Union aim for in a trade deal with Trump? - Bruegel - May 15th, 2025 [May 15th, 2025]
- European Union accuses TikTok of breaching digital rules with lack of transparency on ads - Ottumwa Courier - May 15th, 2025 [May 15th, 2025]
- European Union election observation mission publishes its final report with 19 recommendations; genuine political will needed to reinforce democratic... - May 15th, 2025 [May 15th, 2025]
- Digital Anonymity in Danger! What is the European Union deciding? - Red Hot Cyber - May 15th, 2025 [May 15th, 2025]
- The European Union and the United States reach an agreement to enhance trade talks - - May 15th, 2025 [May 15th, 2025]
- EU and UK at loggerheads over fishing rights and youth mobility | European Union - The Guardian - May 15th, 2025 [May 15th, 2025]
- European Union agrees on 17th sanction package against Russia (VGK:NYSEARCA) - Seeking Alpha - May 14th, 2025 [May 14th, 2025]
- The European Union celebrates Europe Day 2025 with the exhibition Panama and Europe: routes that connect - EEAS - May 14th, 2025 [May 14th, 2025]
- European Union's Nails and Staples Market Expected to Grow at CAGR of +0.9% Over Next Decade - IndexBox - May 14th, 2025 [May 14th, 2025]
- Gavin Willsey reaches milestone at the Midwest Model European Union competition - Stephen F. Austin State University - May 10th, 2025 [May 10th, 2025]
- Europe Day NYC: Celebrating 75 years of the European Union, from vision to reality - EEAS - May 10th, 2025 [May 10th, 2025]
- Meet the MEP who wants to bring Canada into the European Union - Euronews.com - May 10th, 2025 [May 10th, 2025]
- European Union: The European Commission's action plan to drive innovation, sustainability and competitiveness in the automotive sector - Global... - May 10th, 2025 [May 10th, 2025]
- European Union launches $566 million drive to attract researchers scared off by Trump moves on science and universities - Fortune - May 10th, 2025 [May 10th, 2025]
- Georgians Risk Losing Their Visa-Free Travel Privileges To The European Union Amid Growing Tensions - Travel And Tour World - May 10th, 2025 [May 10th, 2025]
- The Delegation of the European Union to the Republic of Korea Marking Europe Day 2025 under the Theme "Partnering for Peace and Security" -... - May 10th, 2025 [May 10th, 2025]
- 'We call on the European Union to endorse a confederation of the states of Israel and Palestine in one homeland' - Le Monde.fr - May 3rd, 2025 [May 3rd, 2025]
- The European Union does not plan to participate in the settlement of the conflict on Ukraine - EADaily - May 3rd, 2025 [May 3rd, 2025]